Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Coronado Biosciences, a company into the development and commercialisation of therapeutic products for the treatment of cancer, has appointed Gary Gemignani as chief operating officer and chief financial officer. Mr Gemignani will be responsible for operational and business development activities and financial management.
Subscribe to our email newsletter
Mr Gemignani brings to Coronado 25 years of accounting, planning and finance experience that includes employment at a broad spectrum of life science businesses including emerging biotech, big pharma and accounting and consultancy.
Additionally, Mr Gemignani was most recently executive vice president and chief financial officer at Gentium, a publicly traded, late-stage biotechnology company focused on the development and manufacturing of drugs to treat and prevent vascular diseases related to cancer.
Prior to joining Gentium, Mr Gemignani held senior financial positions at Novartis, Prudential Financial, Wyeth and Arthur Andersen.
Tesi, president and CEO of Coronado Biosciences, said: “Gary brings operational leadership and finance and management expertise to the company’s executive management team. His range of experience working with both biotech and life science companies will contribute to the success of Coronado.”
Mr Gemignani, said: “Given Coronado Biosciences’ technology, I believe there is value to be unlocked and look forward to working with the management and board to accomplish the company’s goals.”